Ignite Creation Date:
2024-05-06 @ 1:29 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04032080
Status:
COMPLETED
Last Update Posted:
2023-09-11
First Post:
2019-07-23
Brief Title:
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Sponsor:
Baylor Research Institute
Organization:
Baylor Research Institute
Study Overview
Official Title:
Pilot Clinical Trial of Treatment With LY3023414 and Prexasertib to Inhibit Homologous Recombination HR in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer Amendment 1
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer
Detailed Description:
Seventy to eighty percent of breast cancers have a gene expression profile which is characterized by homologous recombination deficiency HRD and high proliferation HRD leads to errors in DNA pathway non -homologous end joining NHEJ that repair DNA-breaks a process required for metastatic triple negative breast cancer TNBC survival The hypothesis of this pilot trial is that administration of LY3023414 and prexasertib will inhibit NHEJ in metastatic TNBC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None